PM,
I don't think that's quite true. I believe if you go back to the SNO presentation discussing the Top 100, or Dr. Ashkan's remarks taking the median survival on the Top 100 to over 7 years you know what you have.
It's true that they could release TLD at any time they wished after they received the results from those hired to gather it, but they know that on releasing such a statement they can't go any deeper into the data until it's been subjected to peer review. Had they released a statement, but waited for a Journal, shorts could attack what they said and they couldn't answer back, not until their answer was quoting peer reviewed information.
It's not uncommon for companies not to release TLD on successful trials until peer review in some form is about to occur. I grant you, they did not have to hold for a Journal publication, I'm quite certain that if Dr. Liau had sent an Abstract to almost any applicable organization having a conference it would have been accepted for presentation. They choose the Journal because it will be a more comprehensive presentation and far less vulnerable to allegations of inadequacies from shorts.
Personally I'd be happy with both, presentation shortly followed by Journal, but that can only happen if it's planned that way and the Journal is ready to publish, but is holding for the presentation. In that scenario the TLD statement would either be out at the time the Abstract became public, or when presentation titles were announced. In the case of ASCO, that's in April or May. As I see it, the Abstract probably reveals slightly more information than the TLD statement, but certainly opens the doors to questions. The presentation would answer most of the questions, but what's left would be covered in depth by the Journal.
As I remember it, Abstract are out for ASCO roughly a week before the conference. Not a lot of time for creating doubt till most of the doubt is answered. The Journal can be issued any day after the presentation is made, so it could come almost immediately. As for the title, any title that didn't specifically say DCVax-L could potentially be for some other trial, so if they didn't wish to acknowledge an ASCO presentation until Abstracts were revealed the title could create speculation, but no one could be certain.
If the Journal was set to publish by late April, and I had the choice to present at ASCO and publish immediately afterword's, I would choose a 5 or 6 weeks delay to have both. I'm sure others would want the publication ASAP. If I did publish prior, I'd probably spring for the $90K for time at the Experts Theater during ASCO. Beside Dr. Liau and other key clinicians I'd probably have some of the longest trial survivors speaking, I believe they did something like that a few years ago.
Gary
AI
Market Data 
Markets 
